Skip to main content

Table 8 Cilengitide Pharmacokinetic Data

From: A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

Parameter (unit)

n

Geomean

Min

Max

Cmax (ng/mL)

11

61163

50100

85500

tmax (h)

11

1*

1

1.25

AUC0-t (ng/mL*h)

11

182069

128234

334829

AUC0- (ng/mL*h)

10

183968

134307

243990

λz (1/h)

10

0.230

0.155

0.278

t1/2 (h)

10

3.0

2.5

4.5

CL (mL/min/m2)

10

54.2

41.0

72.5

Vss (mL/m2)

10

12100

8299

16384

  1. Data are pharmacokinetic parameters of Cilengitide one hour after an intravenous infusion.
  2. *Median is given.
  3. Abbreviations are: n, number; Geomean, geometric mean; Min, minimum; Max, maximum; Cmax, the observed maximum plasma concentration; tmax, time to reach Cmax; AUC, area under the curve; λz, apparent first-order rate constant; t1/2, apparent terminal half-life associated with negative terminal slope; CL, total body clearance of drug from plasma; Vss, volume of distribution at steady state.